The Lancet Oncology in conversation with
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this p...
Insights from recent episode analysis
On the show
- Professor Fred Saad1 ep
- James Nagarajah1 ep
- Ali Landman1 ep
Also: Kayleigh Bhangdia, Dr Dylan Graetz, Dr Erica Kaye, Dr Jesse Plascak, Dr Marissa Baker, Dr Andre Pfob, Prof Peter Dubsky, Dr Gary Rodin, Matthias Preusser, Dr Andrea Necchi, Dr Hedvig Hricak, Dr Zachary Ward, Hans Merks, Professor Sherene Loi, Professor Galina Velikova
Audience Interest
Podcast Focus
Publishing Consistency
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on 1 signal.
Built from
By chart position
- 🇮🇳India · Medicine#364.8K to 25K
- 🇫🇷France · Medicine#162195 to 1.0K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
5.0K to 26K🎙 Biweekly cadence·80 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
7.1K to 38K🇺🇸71%🇮🇳27%🇫🇷1% - Active Followers
Loyal subscribers who consistently listen
2.9K to 15K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/24/26 | breast cancertumour-infiltrating lymphocytes+3 | Professor Sherene Loi | International Immuno-Oncology Biomarker Working GroupThe Lancet Oncology+3 | — | tumour-infiltrating lymphocytesbreast cancer+5 | — | 17m 49s | ||
| 7/27/26 | quality of lifechest wall radiotherapy+3 | Professor Galina Velikova | SUPREMO trialThe Lancet+1 | intermediate-risk breast cancer | quality of lifeSUPREMO trial+5 | — | 11m 48s | ||
| 6/29/26 | imagingosteosarcoma+4 | Hans Merks | The Lancet GroupThe Lancet+1 | — | osteosarcomaEwing sarcoma+4 | — | 12m 39s | ||
| 5/31/26 | cancer workforceglobal health crisis+3 | Dr Hedvig HricakDr Zachary Ward | Memorial Sloan Kettering Cancer CenterHarvard TH Chan School of Public Health+2 | New York, NY, USABoston, MA, USA | cancer workforceglobal crisis+3 | — | 23m 36s | ||
| 4/27/26 | quality of lifemetastatic prostate cancer+3 | Professor Fred Saad | Department of Surgery/Urology, University of MontrealThe Lancet Oncology+1 | Montreal, QC, Canada | metastatic hormone-sensitive prostate cancerquality of life+3 | — | 13m 01s | ||
| 3/30/26 | prostate cancertheranostics+4 | James Nagarajah | [177Lu]-PSMA-617-PSMA-617The Lancet Oncology+1 | — | prostate cancerBULLSEYE+4 | — | 10m 55s | ||
| 3/17/26 | oncological imagingradiology+3 | Ali Landman | The Lancet Medical Imaging & Theranostics | Vienna | oncological imagingradiology+3 | — | 15m 00s | ||
| 3/9/26 | breast cancerepidemiological trends+4 | Kayleigh Bhangdia | GBD | 204 countries | breast cancerGBD study+5 | — | 18m 23s | ||
| 2/2/26 | qualitative researchoncology+3 | Dr Dylan GraetzDr Erica Kaye | St Jude Children’s Research HospitalThe Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research | — | qualitative researchoncology+3 | — | 42m 58s | ||
| 12/29/25 | cancer mortalityoccupation+3 | Dr Jesse PlascakDr Marissa Baker | The Ohio State UniversityUniversity of Washington School of Public Health | — | cancermortality rates+6 | — | 23m 47s | ||
| 11/25/25 | digital healthartificial intelligence+3 | Dr Andre PfobProf Peter Dubsky | Heidelberg University HospitalUniversity of Lucerne+1 | — | digital healthartificial intelligence+3 | — | 26m 34s | ||
| 11/2/25 | cancer carehuman dimensions+3 | Dr Gary Rodin | Lancet OncologyThe Lancet Group | — | cancerhuman crisis+4 | — | 10m 46s | ||
| 10/27/25 | clinical trialsbrain metastases+3 | Matthias Preusser | patritumab deruxtecanMedical University of Vienna+1 | Vienna, Austria | TUXEDO-3patritumab deruxtecan+5 | — | 17m 10s | ||
| 9/29/25 | bladder cancerneoadjuvant therapy+4 | Dr Andrea Necchi | Vita-Salute San Raffaele UniversitySan Raffaele Hospital+1 | — | muscle-invasive bladder cancerTAR-200+4 | — | 12m 15s |
Showing 14 of 80
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for The Lancet Oncology in conversation with
Peaked at #36 in India, currently #36 in India.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| India | — | #36 | #36 | — |
| India | — | #125 | #125 | — |
| France | — | #162 | #162 | — |
Chart Positions
3 placements across 2 markets.
Chart Positions
3 placements across 2 markets.